Antimicrobial compounds, compositions, and uses thereof
Inventors
Sleet, Randolph B. • Kates, Steven A. • Parkinson, Steven
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Antimicrobial compounds and compositions of Formula (I) and methods of use are disclosed.
Core Innovation
The invention relates to antimicrobial compounds defined by Formula (I), including Nu-8 and Compound (I), or pharmaceutically acceptable salts thereof. The disclosed compounds are characterized by a nucleoside scaffold and include phosphate groups and butyl substituents, with salt variants including sodium, ammonium, calcium, potassium, magnesium, and cobalt.
The patent content states that the compound, or a pharmaceutically acceptable salt thereof, is present in protonated form and that, when dissolved in water, it has a pH of about 3 to about 4. It also discusses pH and protonation behavior, physical properties, antimicrobial activity trends across pH, and comparative evaluation versus related compounds including Bisphosphocin 16 11 16 12, Nu-4, and Nu-5.
The patent content further provides pharmaceutical compositions including the compound of Formula (I) or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically acceptable carriers, excipients, or diluents. The compositions are adapted for topical, oral, inhalation, intravesical, and parenteral administration, and the disclosed uses include bacterial infections and indications such as diabetic foot ulcer infection, complicated urinary tract infection/catheter-associated UTI, cystic fibrosis lung infection, ventilator-acquired pneumonia, burn wound infection, otitis externa, bacterial vaginosis, and impetigo.
Claims Coverage
The independent claim coverage centers on antimicrobial compounds of Formula (I) and pharmaceutically acceptable salts, with inventive features directed to protonation state, named salt counterions, pharmaceutical compositions with carriers, excipients, or diluents, and route-specific adaptation. At least six inventive features are represented.
Compound defined by formula (i) or pharmaceutically acceptable salt
A compound having Formula (I), or a pharmaceutically acceptable salt thereof.
Protonated compound with aqueous pH of about 3 to about 4
The compound or salt is protonated such that, when dissolved in water, it has a pH of about 3 to about 4.
Selected pharmaceutically acceptable salts: ammonium, calcium, sodium, potassium, magnesium, cobalt
The pharmaceutically acceptable salts are selected from ammonium, calcium, sodium, potassium, magnesium, and cobalt salts.
Pharmaceutical composition with pharmaceutically acceptable carriers, excipients, or diluents
A pharmaceutical composition includes a compound of Formula (I) or a pharmaceutically acceptable salt together with one or more pharmaceutically acceptable carriers, excipients, or diluents.
Pharmaceutical composition adapted for topical administration
The pharmaceutical composition is adapted for topical administration.
Pharmaceutical composition adapted for intravesical administration
The pharmaceutical composition is adapted for intravesical administration.
Overall, the claim coverage centers on antimicrobial compounds of Formula (I) and their pharmaceutically acceptable salts, with further limitations to protonation behavior, specific named counterions, and pharmaceutical compositions formulated with carriers, excipients, or diluents and adapted to topical and intravesical administration.
Stated Advantages
Unexpectedly high biological activity at less acidic or higher pH, including pH greater than about 3.
Compatibility with topical, inhalation, and intravesical routes.
Effectiveness against slow-growing bacteria.
Demonstrated antimicrobial activity trends across pH for Nu-8.
Bacterial cytological profiling indicating rapid cell envelope disruption and reduced viability for Nu-8.
In vivo efficacy in mice and rats for Helicobacter pylori and E. coli urinary tract infection models.
Evaluation of pH and physical properties of Nu-8 versus Bisphosphocin 16 11 16 12, Nu-4, and Nu-5.
Documented Applications
Treatment of diabetic foot ulcer infection.
Treatment of complicated urinary tract infection/catheter-associated UTI.
Treatment of cystic fibrosis lung infection.
Treatment of ventilator-acquired pneumonia.
Treatment of burn wound infection.
Treatment of otitis externa.
Treatment of bacterial vaginosis.
Treatment of impetigo.
Antimicrobial activity and bacterial cytological profiling for bacterial organisms including H. pylori SS1 and urinary tract infection-associated organisms, with evaluation outcomes reported for Nu-8.
In vivo efficacy in mice and rats for Helicobacter pylori and E. coli urinary tract infection models.
Human use cases for bacterial infections or indications via intravesical administration.
Human use cases for bacterial infections or indications via inhalational administration.
Human use cases for bacterial infections or indications via topical administration.
Human use cases for bacterial infections or indications via other routes including those associated with the listed indications, including diabetic foot ulcer, ventilator acquired pneumonia, bacterial vaginosis, impetigo, otitis externa, and burn wound infection.
Interested in licensing this patent?